Patients ( n = 1948 ) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel ( EC-T ) with or without eight infusions of bevacizumab every 3 weeks before surgery .